Answers are grounded in this paper and cite their sources.
This study examined the longitudinal association of metabolic dysfunction-associated fatty liver disease (MAFLD) with distinct cognitive function trajectories, and determine whether and to what extent this association was mediated by MAFLD-related metabolites among 845 participants. Two cognitive function trajectories were identified as normal (n = 714, 84.50%) or large decrease (n = 131, 15.50%) pattern over 7 years. Participants with MAFLD (N = 277, 32.78%) had an 81% higher risk of developing a large decrease in cognitive function (odds ratio, 1.81; 95% confidence interval, 1.16-2.94) than non-MAFLD. Three MAFLD-related metabolites were identified as lysoPC(20:3(5z,8z,11z)), lysoPE(18:1(9z)/0:0), and valine, of which lysoPE(18:1(9z)/0:0) and valine played a partially mediated role in the association of MAFLD with a large decrease in cognitive function (mediation proportion = 9.93% and 11.04%, respectively). The results indicated that MAFLD was associated with a higher risk of developing a large decrease in cognitive function, which was partially mediated by lipid and amino acid metabolism.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: